(R)-2-(4-((((9H-fluoren-9-yl)methoxy)carbonylamino)(2,4-dimethoxyphenyl)methyl)phenoxy)acetic acid | 1270012-13-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (R)-2-(4-((((9H-fluoren-9-yl)methoxy)carbonylamino)(2,4-dimethoxyphenyl)methyl)phenoxy)acetic acid
• 英文别名: (R)-2-(4-(((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)(2,4-dimethoxyphenyl)methyl)phenoxy)acetic acid；2-[4-[(R)-(2,4-dimethoxyphenyl)-(9H-fluoren-9-ylmethoxycarbonylamino)methyl]phenoxy]acetic acid
• CAS: 1270012-13-9
• 化学式: C₃₂H₂₉NO₇
• 分子量: 539.585
• InChiKey: UPMGJEMWPQOACJ-WJOKGBTCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION
  申请人：Becker Katja

  公开号：US20130266645A1

  公开（公告）日：2013-10-10

  The present invention relates to compounds derived from steroids of the general formula (I) wherein L represents a linker and R # represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).

  本发明涉及一般式(I)的类固醇衍生物，其中L代表连接剂，R#代表类固醇残基，以及一般式(I)化合物在医学中的使用以及用于传染病的预防和/或治疗。此外，还描述了包含至少一种一般式(I)化合物的药物组合物。本发明的另一个方面涉及一般式(I)化合物的合成。
• Oligoribonucleotides with amide backbone
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0714907A1

  公开（公告）日：1996-06-05

  Oligomers having amide linkages of the following formula:    wherein R¹ is H, C₁₋₄ alkyl, C₁₋₁₈-acyl or hydroxy-lower alkyl; R² is H, aralkyl, or C₁₋₄ alkyl; B is a nucleoside base residue selected from the group consisting of adenine, cytosine, guanine, thymine, uracil; X is H, OR¹, NHR² or NH-acyl; Y is OR² or NHR²; and n is a number from 5 through 25, and salts thereof.

  以下式具有酰胺键的寡聚体： 其中R¹为H、C₁₋₄烷基、C₁₋₁₈酰基或羟基较低烷基；R²为H、芳基烷基或C₁₋₄烷基；B为从腺嘌呤、胞嘧啶、鸟嘌呤、胸腺嘧啶、尿嘧啶组成的核苷酸碱基残基；X为H、OR¹、NHR²或NH-酰基；Y为OR²或NHR²；n为从5到25的数字，以及其盐。
• THERAPEUTICALLY ACTIVE ALPHA MSH ANALOGUES
  申请人：Jonassen Thomas E.N.

  公开号：US20090069242A1

  公开（公告）日：2009-03-12

  The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.

  该发明描述了α-黑色素细胞刺激激素（a-MSH）的肽类类似物，与天然α-MSH肽相比具有更高的效力。α-MSH类似物表现出比α-MSH更强的抗炎作用和预防缺血状况的能力。该发明进一步揭示了利用这些肽制造用于治疗或预防哺乳动物的一个或多个器官组织中的疾病的制药组合物，以及制药组合物的用途。
• APOA-1 PEPTIDE MIMETICS
  申请人：Bianchi Elisabetta

  公开号：US20110046056A1

  公开（公告）日：2011-02-24

  The invention relates to peptide mimetics for treating disorders associated with hypercholesterolemia and cardio-vascular disease. In particular, the invention relates to peptides that mimic the activity of apolipoprotein A-I (Apo AI).

  本发明涉及用于治疗与高胆固醇血症和心血管疾病有关的疾病的肽类类似物。具体而言，本发明涉及模拟载脂蛋白A-I（Apo AI）活性的肽类。
• Therapeutically Active Alpha-MSH Analogues
  申请人：AbbVie Inc.

  公开号：US20130252891A1

  公开（公告）日：2013-09-26

  The invention describes peptide analogues of α-melanocyte-stimulating hormone (α-MSH), which possess an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.

  该发明描述了α-黑素细胞刺激激素（α-MSH）的肽类类似物，与天然的α-MSH肽相比具有更高的功效。α-MSH类似物表现出比α-MSH更强的抗炎作用和预防缺血症状的能力。该发明进一步揭示了利用这些肽制造药物组合物，用于治疗或预防哺乳动物器官组织中的某种疾病，并且制造了药物组合物。